Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 37

1.

Drug monitoring of tamoxifen metabolites predicts vaginal dryness and verifies a low discontinuation rate from the Norwegian Prescription Database.

Helland T, Hagen KB, Haugstøyl ME, Kvaløy JT, Lunde S, Lode K, Lind RA, Gripsrud BH, Jonsdottir K, Gjerde J, Bifulco E, Hustad S, Jonassen J, Aas T, Lende TH, Lien EA, Janssen EAM, Søiland H, Mellgren G.

Breast Cancer Res Treat. 2019 Aug;177(1):185-195. doi: 10.1007/s10549-019-05294-w. Epub 2019 May 29.

PMID:
31144152
2.

Prognostic impact of genetic variants of CYP19A1 and UGT2B17 in a randomized trial for endocrine-responsive postmenopausal breast cancer.

Johansson H, Aristarco V, Gandini S, Gjerde J, Macis D, Guerrieri-Gonzaga A, Serrano D, Lazzeroni M, Rajasekaran A, Williard CV, Mellgren G, DeCensi A, Bonanni B.

Pharmacogenomics J. 2019 Apr 10. doi: 10.1038/s41397-019-0087-z. [Epub ahead of print]

PMID:
30967597
3.

The lucky ones get cured: Health care seeking among women with pelvic organ prolapse in Amhara Region, Ethiopia.

Gjerde JL, Rortveit G, Adefris M, Mekonnen H, Belayneh T, Blystad A.

PLoS One. 2018 Nov 26;13(11):e0207651. doi: 10.1371/journal.pone.0207651. eCollection 2018.

4.

Life after pelvic organ prolapse surgery: a qualitative study in Amhara region, Ethiopia.

Gjerde JL, Rortveit G, Adefris M, Belayneh T, Blystad A.

BMC Womens Health. 2018 May 29;18(1):74. doi: 10.1186/s12905-018-0568-2.

5.

Strengthening validity in studies of pelvic floor disorders through qualitative research: an example from Ethiopia.

Blystad A, Rortveit G, Gjerde JL, Muleta M, Moland KM.

Int Urogynecol J. 2018 May;29(5):679-684. doi: 10.1007/s00192-017-3515-0. Epub 2017 Nov 18.

PMID:
29151168
6.

A pooled analysis of CYP2D6 genotype in breast cancer prevention trials of low-dose tamoxifen.

Johansson H, Gandini S, Serrano D, Gjerde J, Lattanzi M, Macis D, Guerrieri-Gonzaga A, Aristarco V, Mellgren G, Lien E, DeCensi A, Bonanni B.

Breast Cancer Res Treat. 2016 Aug;159(1):97-108. doi: 10.1007/s10549-016-3932-7. Epub 2016 Aug 2.

PMID:
27484880
7.

Living with pelvic organ prolapse: voices of women from Amhara region, Ethiopia.

Gjerde JL, Rortveit G, Muleta M, Adefris M, Blystad A.

Int Urogynecol J. 2017 Mar;28(3):361-366. doi: 10.1007/s00192-016-3077-6. Epub 2016 Jul 30.

8.

Background Stress Inventory: Developing a Measure of Understudied Stress.

Terrill AL, Gjerde JM, Garofalo JP.

Stress Health. 2015 Oct;31(4):290-8. doi: 10.1002/smi.2554. Epub 2013 Nov 26.

PMID:
26468688
9.

Estrogens Correlate with PELP1 Expression in ER Positive Breast Cancer.

Flågeng MH, Knappskog S, Gjerde J, Lønning PE, Mellgren G.

PLoS One. 2015 Aug 6;10(8):e0134351. doi: 10.1371/journal.pone.0134351. eCollection 2015.

10.

The active tamoxifen metabolite endoxifen (4OHNDtam) strongly down-regulates cytokeratin 6 (CK6) in MCF-7 breast cancer cells.

Helland T, Gjerde J, Dankel S, Fenne IS, Skartveit L, Drangevåg A, Bozickovic O, Flågeng MH, Søiland H, Mellgren G, Lien EA.

PLoS One. 2015 Apr 13;10(4):e0122339. doi: 10.1371/journal.pone.0122339. eCollection 2015.

11.

Illness uncertainty in breast cancer patients: validation of the 5-item short form of the Mishel Uncertainty in Illness Scale.

Hagen KB, Aas T, Lode K, Gjerde J, Lien E, Kvaløy JT, Lash TL, Søiland H, Lind R.

Eur J Oncol Nurs. 2015 Apr;19(2):113-9. doi: 10.1016/j.ejon.2014.10.009. Epub 2014 Dec 20.

PMID:
25538036
12.

Phospholipids from herring roe improve plasma lipids and glucose tolerance in healthy, young adults.

Bjørndal B, Strand E, Gjerde J, Bohov P, Svardal A, Diehl BW, Innis SM, Berger A, Berge RK.

Lipids Health Dis. 2014 May 17;13:82. doi: 10.1186/1476-511X-13-82.

13.

Serum concentrations of tamoxifen and its metabolites increase with age during steady-state treatment.

Lien EA, Søiland H, Lundgren S, Aas T, Steen VM, Mellgren G, Gjerde J.

Breast Cancer Res Treat. 2013 Sep;141(2):243-8. doi: 10.1007/s10549-013-2677-9. Epub 2013 Sep 1.

14.

A randomized phase II presurgical trial of weekly low-dose tamoxifen versus raloxifene versus placebo in premenopausal women with estrogen receptor-positive breast cancer.

Serrano D, Lazzeroni M, Gandini S, Macis D, Johansson H, Gjerde J, Lien E, Feroce I, Pruneri G, Sandri M, Bassi F, Brenelli F, Luini A, Cazzaniga M, Varricchio C, Guerrieri-Gonzaga A, DeCensi A, Bonanni B.

Breast Cancer Res. 2013 Jun 20;15(3):R47. doi: 10.1186/bcr3439.

15.

Changes in adipose glucocorticoid metabolism before and after bariatric surgery assessed by direct hormone measurements.

Methlie P, Dankel S, Myhra T, Christensen B, Gjerde J, Fadnes D, Våge V, Løvås K, Mellgren G.

Obesity (Silver Spring). 2013 Dec;21(12):2495-503. doi: 10.1002/oby.20449. Epub 2013 Jun 13.

16.

Breaking away: high fracture rates may merit a new trial of adjuvant endocrine therapy in Scandinavian breast cancer patients.

Søiland H, Hagen KB, Gjerde J, Lende TH, Lien EA.

Acta Oncol. 2013 May;52(4):861-2. doi: 10.3109/0284186X.2012.742963. Epub 2012 Nov 29. No abstract available.

PMID:
23193962
17.

Silently waiting to heal: experiences among women living with urinary incontinence in northwest Ethiopia.

Gjerde JL, Rortveit G, Muleta M, Blystad A.

Int Urogynecol J. 2013 Jun;24(6):953-8. doi: 10.1007/s00192-012-1951-4. Epub 2012 Nov 6.

PMID:
23129246
18.

Steroid receptor coactivators, HER-2 and HER-3 expression is stimulated by tamoxifen treatment in DMBA-induced breast cancer.

Moi LL, Flågeng MH, Gjerde J, Madsen A, Røst TH, Gudbrandsen OA, Lien EA, Mellgren G.

BMC Cancer. 2012 Jun 15;12:247. doi: 10.1186/1471-2407-12-247.

19.

Tissue distribution of 4-hydroxy-N-desmethyltamoxifen and tamoxifen-N-oxide.

Gjerde J, Gandini S, Guerrieri-Gonzaga A, Haugan Moi LL, Aristarco V, Mellgren G, Decensi A, Lien EA.

Breast Cancer Res Treat. 2012 Jul;134(2):693-700. doi: 10.1007/s10549-012-2074-9. Epub 2012 May 5.

20.

The nuclear receptors NUR77, NURR1 and NOR1 in obesity and during fat loss.

Veum VL, Dankel SN, Gjerde J, Nielsen HJ, Solsvik MH, Haugen C, Christensen BJ, Hoang T, Fadnes DJ, Busch C, Våge V, Sagen JV, Mellgren G.

Int J Obes (Lond). 2012 Sep;36(9):1195-202. doi: 10.1038/ijo.2011.240. Epub 2011 Dec 6.

PMID:
22143616
21.

Functional polymorphisms in UDP-glucuronosyl transferases and recurrence in tamoxifen-treated breast cancer survivors.

Ahern TP, Christensen M, Cronin-Fenton DP, Lunetta KL, Søiland H, Gjerde J, Garne JP, Rosenberg CL, Silliman RA, Sørensen HT, Lash TL, Hamilton-Dutoit S.

Cancer Epidemiol Biomarkers Prev. 2011 Sep;20(9):1937-43. doi: 10.1158/1055-9965.EPI-11-0419. Epub 2011 Jul 12.

22.

Associations between tamoxifen, estrogens, and FSH serum levels during steady state tamoxifen treatment of postmenopausal women with breast cancer.

Gjerde J, Geisler J, Lundgren S, Ekse D, Varhaug JE, Mellgren G, Steen VM, Lien EA.

BMC Cancer. 2010 Jun 21;10:313. doi: 10.1186/1471-2407-10-313.

23.

Effect of low-dose tamoxifen on steroid receptor coactivator 3/amplified in breast cancer 1 in normal and malignant human breast tissue.

Haugan Moi LL, Hauglid Flågeng M, Gandini S, Guerrieri-Gonzaga A, Bonanni B, Lazzeroni M, Gjerde J, Lien EA, DeCensi A, Mellgren G.

Clin Cancer Res. 2010 Apr 1;16(7):2176-86. doi: 10.1158/1078-0432.CCR-09-1859. Epub 2010 Mar 23. Erratum in: Clin Cancer Res. 2010 Oct 15;16(20):5087. De Censi, Andrea [corrected to DeCensi, Andrea].

24.

Efficacy of tamoxifen based on cytochrome P450 2D6, CYP2C19 and SULT1A1 genotype in the Italian Tamoxifen Prevention Trial.

Serrano D, Lazzeroni M, Zambon CF, Macis D, Maisonneuve P, Johansson H, Guerrieri-Gonzaga A, Plebani M, Basso D, Gjerde J, Mellgren G, Rotmensz N, Decensi A, Bonanni B.

Pharmacogenomics J. 2011 Apr;11(2):100-7. doi: 10.1038/tpj.2010.17. Epub 2010 Mar 23.

PMID:
20309015
25.

Uncertainty during the transition from cancer patient to survivor.

Garofalo JP, Choppala S, Hamann HA, Gjerde J.

Cancer Nurs. 2009 Jul-Aug;32(4):E8-E14. doi: 10.1097/NCC.0b013e31819f1aab.

26.

Tamoxifen impairs both longitudinal and cortical bone growth in young male rats.

Karimian E, Chagin AS, Gjerde J, Heino T, Lien EA, Ohlsson C, Sävendahl L.

J Bone Miner Res. 2008 Aug;23(8):1267-77. doi: 10.1359/jbmr.080319.

27.

Effects of CYP2D6 and SULT1A1 genotypes including SULT1A1 gene copy number on tamoxifen metabolism.

Gjerde J, Hauglid M, Breilid H, Lundgren S, Varhaug JE, Kisanga ER, Mellgren G, Steen VM, Lien EA.

Ann Oncol. 2008 Jan;19(1):56-61. Epub 2007 Oct 18.

PMID:
17947222
28.

Randomized dose-ranging trial of tamoxifen at low doses in hormone replacement therapy users.

Decensi A, Gandini S, Serrano D, Cazzaniga M, Pizzamiglio M, Maffini F, Pelosi G, Daldoss C, Omodei U, Johansson H, Macis D, Lazzeroni M, Penotti M, Sironi L, Moroni S, Bianco V, Rondanina G, Gjerde J, Guerrieri-Gonzaga A, Bonanni B.

J Clin Oncol. 2007 Sep 20;25(27):4201-9. Epub 2007 Aug 20.

PMID:
17709798
29.

Pretreatment with tamoxifen does not change acute epirubicin cardiotoxicity in rats.

Schjøtt J, Gjerde J, Kisanga ER, Lien EA.

Basic Clin Pharmacol Toxicol. 2006 Feb;98(2):231-4. No abstract available.

30.

Identification and quantification of tamoxifen and four metabolites in serum by liquid chromatography-tandem mass spectrometry.

Gjerde J, Kisanga ER, Hauglid M, Holm PI, Mellgren G, Lien EA.

J Chromatogr A. 2005 Jul 29;1082(1):6-14.

PMID:
16038189
31.

Induction of hepatic drug-metabolising enzymes and tamoxifen metabolite profile in relation to administration route during low-dose treatment in nude rats.

Kisanga ER, Moi LL, Gjerde J, Mellgren G, Lien EA.

J Steroid Biochem Mol Biol. 2005 Apr;94(5):489-98. Epub 2005 Apr 7.

PMID:
15876414
32.

Tamoxifen and metabolite concentrations in serum and breast cancer tissue during three dose regimens in a randomized preoperative trial.

Kisanga ER, Gjerde J, Guerrieri-Gonzaga A, Pigatto F, Pesci-Feltri A, Robertson C, Serrano D, Pelosi G, Decensi A, Lien EA.

Clin Cancer Res. 2004 Apr 1;10(7):2336-43.

33.

Tamoxifen administration and metabolism in nude mice and nude rats.

Kisanga ER, Gjerde J, Schjøtt J, Mellgren G, Lien EA.

J Steroid Biochem Mol Biol. 2003 Feb;84(2-3):361-7.

PMID:
12711024
35.

Isolation and characterization of Vibrio alginolyticus and Vibrio parahaemolyticus from the Norwegian coastal environment.

Gjerde J, Böe B.

Acta Vet Scand. 1981;22(3-4):331-43. No abstract available.

PMID:
7344524
36.
37.

[A bacteriological investigation of Norwegian cod liver oil (author's transl)].

Gjerde J, Lied E.

Nord Vet Med. 1975 Apr;27(4):224-8. Norwegian.

PMID:
1144018

Supplemental Content

Loading ...
Support Center